Litigation Details for Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
✉ Email this page to a colleague
Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-05-16 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:183 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Referred To | ||
| Patents | 9,827,231 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ferring Pharmaceuticals Inc. v. Lupin Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-06-22 | 91 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,827,231 (“the ’231 patent”) and 9,669,110 (“the ’110 patent”). (D.I. 1). …using the composition. (’231 patent, claims 1 and 14). The ’110 patent claims a method of timing a colonoscopy…colonoscopy procedure. (’110 patent, claim 1). Only the ’110 patent is at issue in Defendants’ motion…of the ’110 patent. (Id. at 8). “Whoever actively induces infringement of a patent shall be liable…generic of Plaintiffs’ product. (Id. at 3). The ’231 patent claims a composition of sodium picosulfate, magnesium | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
